Postmarketing Safety Surveillance
The safety profile of a drug evolves over its lifetime on the market; there are bound to be changes in the circumstances of a drug’s clinical use which may give rise to previously unobserved adverse effects, hence necessitating surveillance postmarketing. Postmarketing surveillance has traditionally been carried out by systematic manual review of spontaneous reports of adverse drug reactions. Vast improvements in computing capabilities have provided opportunities to automate signal detection, and several worldwide initiatives are exploring new approaches to facilitate earlier detection, primarily through mining of routinely-collected data from electronic healthcare records (EHR). This paper provides an overview of ongoing initiatives exploring data from EHR for signal detection vis-à-vis established spontaneous reporting systems (SRS). We describe the role SRS has played in regulatory decision making with respect to safety issues, and evaluate the potential added value of EHR-based signal detection systems to the current practice of drug surveillance. Safety signal detection is both an iterative and dynamic process. It is in the best interest of public health to integrate and understand evidence from all possibly relevant information sources on drug safety. Proper evaluation and communication of potential signals identified remains an imperative and should accompany any signal detection activity.
KeywordsTemafloxacin Spontaneous Reporting System Vaccine Adverse Event Reporting System Safety Surveillance Common Data Model
The authors would like to thank Dr. Hector Izurieta of the US FDA, and Dr. Jim Slattery of the European Medicines Agency for reviewing the manuscript.
No sources of funding were used to prepare this manuscript.
Conflict of interest
Miriam Sturkenboom is running a research group that occasionally performs studies for pharmaceutical companies according to unconditional grants. These companies include AstraZeneca, Pfizer, Lilly and Boehringer. She has also been a consultant to Pfizer, Novartis, Consumer Health, Servier, Celgene and Lundbeck on issues not related to this paper. Vaishali Patadia is an employee of Astellas Pharma; the views expressed in this paper are her personal views and do not reflect the views of Astellas Pharma. Preciosa M. Coloma and Gianluca Trifirò have no conflicts of interest to declare that are directly relevant to the content of this review.
- 5.US FDA. FDA issues public health warning on phenylpropanolamine. Available from URL: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm150763.htm. Accessed 9 Jan 2013.
- 6.US FDA. FDA requires additional labeling for over-the-counter pain relievers and fever reducers to help consumers use products safely. Available from URL: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm149573.htm. Accessed 9 Jan 2013.
- 9.DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA Spontaneous Reporting System. Am Stat. 1999;53:177–202.Google Scholar
- 13.Bate A, Edwards IR. Data mining techniques in pharmacovigilance. In: Hartzema AG, Tilson HH, Chan KA, editors. Pharmacoepidemiology and therapeutic risk management. Cincinnati: Harvey Whitney; 2008.Google Scholar
- 18.World Health Organization. Safety of medicines: a guide to detecting and reporting adverse drug reactions 2002. Available from URL: http://whqlibdoc.who.int/hq/2002/WHO_EDM_QSM_2002.2.pdf Accessed 10 Jul 2011.
- 19.Report of CIOMS Working Group VIII. Practical aspects of signal detection in pharmacovigilance. Geneva: WHO; 2010.Google Scholar
- 21.US FDA. FDA Adverse Event Reporting System (AERS). Available from URL: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm. Accessed 2013 Jan 9.
- 22.Vaccine Adverse Event Reporting System. Available from URL: http://vaers.hhs.gov/index/about/index. Accessed 2013 Jan 9.
- 23.European Medicines Agency. EudraVigilance. Available from URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000239.jsp&mid=WC0b01ac05800250b5. Accessed 9 Jan 2013.
- 24.European Medicines Agency. 2009 EudraVigilance-human status report. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/10/WC500097692.pdf. Accessed 9 Jan 2013.
- 25.The Uppsala Monitoring Centre. The WHO programme. Available from URL: http://www.who-umc.org/DynPage.aspx?id=98078&mn1=7347&mn2=7252&mn3=7322. Accessed 20 Apr 2012.
- 26.Uppsala Monitoring Centre. Uppsala reports, 2012 April. Available from URL: http://www.who-umc.org/graphics/26656.pdf. Accessed 29 May 2012.
- 28.Koutkias V, Niès J, Jensen S, et al., editors. Patient safety informatics: adverse drug events, human factors, and IT tools for patient medication safety, vol. 166. Studies in health technology and informatics. IOS Press; 2011.Google Scholar
- 37.Darpö B. Detection and reporting of drug-induced proarrhythmias: room for improvement. Europace. 2007;9 Suppl. 4:iv23–36.Google Scholar
- 40.US Food and Drug Administration. FDA announces withdrawal fenfluramine and dexfenfluramine. Available from URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm179871.htm. Accessed 18 Oct 2011.
- 44.Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep. 1999;48(43):1007.Google Scholar
- 45.Intussusception among recipients of rotavirus vaccine: United States, 1998–1999. MMWR Morb Mortal Wkly Rep. 1999;48(27):577–81.Google Scholar
- 48.Update: Guillain–Barre syndrome among recipients of Menactra meningococcal conjugate vaccine: United States, June 2005–September 2006. MMWR Morb Mortal Wkly Rep. 2006;55(41):1120–4.Google Scholar
- 51.Merck pulls arthritis drug Vioxx from market. Available from URL: http://www.npr.org/templates/story/story.php?storyId=4054991. Accessed 11 Nov 2011.
- 53.Goldman S. Limitations and strengths of spontaneous reports data. Clin Ther. 1998;20 Suppl. C:C40–4.Google Scholar
- 56.Institute of Medicine. The future of drug safety: promoting and protecting the health of the public. Available from URL: http://www.iom.edu/Reports/2006/The-Future-of-Drug-Safety-Promoting-and-Protecting-the-Health-of-the-Public.aspx. Accessed 20 Oct 2011.
- 62.US FDA. The FDA Sentinel initiative. Available from URL: http://www.fda.gov/Safety/FDAsSentinelInitiative. Accessed 12 Jul 2011.
- 63.Mini-Sentinel. Available from URL: http://mini-sentinel.org/ Accessed 15 Feb 2011.
- 64.Mini-Sentinel. Statistical methods development. Available from URL: http://mini-sentinel.org/methods/methods_development/default.aspx. Accessed 31 May 2012.
- 66.Observational Medical Outcomes Partnership. Health outcomes of interest library. Available from URL: http://omop.fnih.org/HOI. Accessed 11 Nov 2011.
- 67.Observational Medical Outcomes Partnership. OMOP Cup 2010. Available from URL: http://omop.fnih.org/omopcup. Accessed 10 Oct 2011.
- 68.Observational Medical Outcomes Partnership. OMOP 2011 symposium presentations. Available from URL: http://omop.fnih.org/OMOP2011Symposium. Accessed 30 Mar 2012.
- 69.Exploring and Understanding Adverse Drug Reactions by Integrative Mining of Clinical records and Biomedical Knowledge. The EU-ADR Project. Available from URL: http://www.euadr-project.org. Accessed 12 Jul 2011.
- 72.Canadian Institutes of Health Research. About the drug safety effectiveness network. Available from URL: http://www.cihr-irsc.gc.ca/e/40269.html. Accessed Mar 2012.
- 73.Innovative Medicines Initiative. PROTECT project. Available from URL: http://www.imi-protect.eu/. Accessed Mar 2012.
- 74.Global Research in Paediatrics. Available from URL: http://www.grip-network.org/. Accessed 10 May 2012.
- 80.Bate A, Edwards IR, Edwards J, et al. Knowledge finding in IMS disease analyzer Mediplus UK database: effective data mining in longitudinal patient safety data. ISOP Annual Meeting: Pharmacovigilance—Current and Future Challenges, Dublin; 6–8 Oct 2004.Google Scholar
- 85.Lieu TA, Kulldorff M, Davis RL, et al. Real-time vaccine safety surveillance for the early detection of adverse events. Med Care. 2007;45(10 Suppl. 2):S89–95.Google Scholar
- 88.Observational Medical Outcomes Partnership. OMOP methods library. Available from URL: http://omop.fnih.org/Methods. Accessed 20 May 2012.
- 89.Zorych I, Madigan D, Ryan P, et al. Disproportionality methods for pharmacovigilance in longitudinal observational databases. Stat Methods Med Res. 2011 [Epub ahead of print].Google Scholar
- 90.Coloma P, Schuemie MJ, Trifiro G, et al. Comparison of methods for drug safety signal detection using electronic healthcare record (EHR) databases: the added value of longitudinal, time-stamped patient information. Presented at the 27th international conference on pharmacoepidemiology and therapeutic risk management, Chicago; 14–17 Aug 2011.Google Scholar
- 96.Daily Med. Trovafloxacin drug label. Available from URL: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=442&CFID=66575927&CFTOKEN=a17d753a0754a3fb-24987D34-D80B-CD9C-39F668DB8C41A045&jsessionid=ca30e46b22b0112063a4. Accessed 13 Jul 2011.
- 97.Daily Med. Rosiglitazone drug label. Available from URL: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=38243. Accessed 13 Jul 2011.
- 98.European Medicines Agency. Tysabri (natalizumab). Available from URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000603/human_med_001119.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124. Accessed 13 Jul 2011.
- 99.MHRA. Dopamine agonists for Parkinson’s disease. Available from URL: http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Product-specificinformationandadvice-A-F/DopamineagonistsforParkinson146sdisease/index.htm. Accessed 13 Jul 2011.
- 100.European Commission. A guideline on summary of product characteristics. Available from URL: http://ec.europa.eu/health/files/eudralex/vol-2/c/smpc_guideline_rev2_en.pdf. Accessed 20 Apr 2012.
- 102.Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies D, editor. Textbook of adverse drug reactions. 3rd ed. Oxford: Oxford University Press; 1985.Google Scholar
- 104.Fung M, Thornton A, Mybeck K, et al. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets—1960 to 1999. Drug Inf J. 2001;35:293–317.Google Scholar